<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01943851</url>
  </required_header>
  <id_info>
    <org_study_id>116183</org_study_id>
    <nct_id>NCT01943851</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies</brief_title>
  <official_title>A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label repeat dose, multicenter, 2-part study to determine the maximum
      tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for GSK525762 given once-daily
      orally. Part 1 of the study is a dose escalation phase to select the recommended Part 2 dose
      (RP2D) based on the safety, PK, and PD profiles observed after oral administration of
      GSK525762. Eligible subjects with relapsed refractory hematological malignancies will be
      enrolled in the dosing cohorts until a MTD is established. Subjects may continue treatment
      in the study until disease progression, unacceptable toxicity, withdrawal of consent, or
      commercial supply of GSK525762 becomes available to the subject. An expansion cohort (Part
      2) is planned in subjects with acute leukemias to further explore clinical activity at the
      MTD. This is the first study of this agent to be conducted in subjects with these relapsed
      and/or refractory hematological malignancies for which no standard therapies are anticipated
      to result in a durable remission.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part 1: Safety and tolerability as assessed by adverse events (AEs), serious adverse events (SAEs), dose limiting toxicity (DLT), dose reductions or delays, withdrawals due to toxicities</measure>
    <time_frame>DLTs up to first 3 weeks and follow-up for up to 24 months after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>A dose-limiting toxicity (DLT) is defined as a clinically significant AE or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and occurring during the first 3 weeks after administration of the first dose that meets protocol defined criteria for DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Safety and tolerability as assessed by changes in safety assessments (e.g., laboratory parameters, vital signs, and cardiac parameters).</measure>
    <time_frame>DLTs up to first 3 weeks and follow-up for up to 24 months after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety and tolerability assessment includes: routine physical examinations, vital sign measurements, echocardiograms, and monitoring of AEs, cardiac safety monitoring consisting of at least 48 hours of telemetry following the first dose, 24 hours of Holter monitoring and triplicate 12-lead ECGs. Laboratory testing includes: hematology, clinical chemistry, pancreatic, coagulation, and liver chemistry panels, testing for troponin, B-type Natriuretic Peptide (BNP), c-peptide, 1,5-Anhydroglucitol (1, 5 AG), Hemoglobin A1c (HbA1c), and thyroid monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective response rate per response criteria.</measure>
    <time_frame>Up to 24 months after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response rate is defined as the percentage of subjects who achieved Complete Response (CR), CRp (as per CR but platelet count &lt;100 x 10^9/L), Partial Response (PR) and a morphologic leukemia-free state among subjects who received at least one dose of treatment in the target population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: GSK525762 PK parameters following single- (Day 1) and repeat-dose (Day 15) administration of GSK525762</measure>
    <time_frame>Week 1 (Days 1, 2,5), Week 2 (Day 4,6,7), Week 3, week 7 and for subjects on study longer than 12 weeks, collect a pre-dose PK sample every 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters include: Area under concentration-time curve(AUC), Minimum observed concentration (Cmin), Pre-dose (trough) concentration at the end of a dosing interval (Ctau), Maximum observed concentration (Cmax), Time of maximum concentration (tmax), Apparent terminal half-life (t1/2) (or t1/2, eff), time invariance and accumulation ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Changes in cardiac QT duration corrected for heart rate by Fridericia's formula (QTcF) and other safety parameters</measure>
    <time_frame>During weeks 1, 2, 3, 4, 5, 7, and 10 and then every three weeks up to 24 month after last dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in cardiac QTcF dose and other safety assessment in relation to GSK525762 exposure markers including dose concentration, Cmax, AUC, following single and repeat-dose oral administration of GSK525762 will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Dose related change in molecular markers in tumor tissue and/or peripheral blood samples.</measure>
    <time_frame>Up to 24 months after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor tissue and/or peripheral blood samples will be collected for the assessment of dose related change in molecular markers (e.g., gene transcription and/or expression of proteins regulated by Bromodomain [BRD] proteins)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: PK/PD relationship between GSK525762 exposure markers and safety and efficacy parameters.</measure>
    <time_frame>Up to 24 months after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The relationship between QTcF and concentration of GSK525762 include: Cmax, average observed concentration (Cav), and instantaneous time-matched concentration. Safety (biomarkers of interest; changes in troponin levels) and efficacy (overall tumor burden) parameters and will be measured against summary exposure measures (e.g., Cmax, pre-dose (trough) concentration at the end of a dosing interval (Ctau), and Cav).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Safety and tolerability assessment of GSK525762 at RP2D.</measure>
    <time_frame>Up to 24 months after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety and tolerability assessment at RP2D includes: routine physical examinations, vital sign measurements, echocardiograms, and monitoring of AEs, cardiac safety monitoring consisting of at least 48 hours of telemetry following the first dose, 24 hours of Holter monitoring and triplicate 12-lead ECGs. Laboratory testing at RP2D includes: hematology, clinical chemistry, pancreatic, coagulation, and liver chemistry panels, testing for troponin, B-type Natriuretic Peptide (BNP), c-peptide, 1,5-Anhydroglucitol (1, 5 AG), Hemoglobin A1c (HbA1c), and thyroid monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Dose related change in molecular markers in tumor tissue and/or peripheral blood samples.</measure>
    <time_frame>Up to 24 to months after last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor tissue and/or peripheral blood samples will be collected for the assessment of dose related change in molecular markers (e.g., gene transcription and/or expression of proteins regulated by BRD proteins)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered with a 5 milligram (mg) starting dose of GSK525762, oral tablets, once daily. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues.  Dose escalation will continue until an MTD is determined or until a dose of 100 mg per day is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK525762</intervention_name>
    <description>GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.</description>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Written informed consent provided.

          -  Males and females 18 years old or older.

          -  In Part 1, subjects must have relapsed and/or refractory hematologic malignancies
             (leukemias, myeloproliferative neoplasms, lymphomas, and myelomas) for which no
             standard therapies are available or anticipated to result in remission. In Part 2,
             subjects must have a diagnosis of relapsed and/or refractory Acute Myeloid Leukemia
             (AML). AML subjects &gt;=65 years of age who are not candidates for or have refused
             standard chemotherapy.

          -  Subjects who have previously received an autologous stem cell transplant are allowed
             if a minimum of 3 months has elapsed from the time of transplant (T0) and the subject
             has recovered from transplant-associated toxicities prior to the first dose of
             GSK525762.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt;=1.

          -  Subject must be stable enough to be expected to complete dosing through the DLT
             observation period as assessed by the investigator.

          -  Able to swallow and retain orally administered medication and does not have any
             clinically significant gastrointestinal abnormalities that may alter absorption such
             as malabsorption syndrome or major resection of the stomach or bowels.

          -  A female subject is eligible to participate if she is of:  Non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy;
             or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable
             cases, a blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40
             milli-International units per milliliter and estradiol &lt; 40 picograms per milliliter
             (&lt; 140 picomole per liter) is confirmatory]. Females on hormone replacement therapy
             (HRT) and whose menopausal status is in doubt will be required to use one of the
             contraception methods defined in protocol if they wish to continue their HRT during
             the study. Otherwise, they must discontinue HRT to allow confirmation of
             post-menopausal status prior to study enrolment. For most forms of HRT, at least two
             to four weeks will elapse between the cessation of therapy and the blood draw; this
             interval depends on the type and dosage of HRT. Following confirmation of their
             post-menopausal status, they can resume use of HRT during the study without use of a
             contraceptive method;  Child-bearing potential and agrees to use one of the
             contraception methods for an appropriate period of time (as determined by the product
             label or investigator) prior to the start of dosing to sufficiently minimize the risk
             of pregnancy at that point. Female subjects must agree to use contraception until at
             least 4 weeks after the last dose of study medication; Negative serum pregnancy test
             â‰¤ 7 days prior to first study drug dose; Female subjects who are lactating must
             discontinue nursing prior to the first dose of study treatment and must refrain from
             nursing throughout the treatment period and for 5 half-lives of GSK525762 or at least
             28 days (whichever is longer) following the last dose of study treatment.

          -  Male subjects must agree to use one of the methods of contraception specified. This
             method must be used from the time of the first dose of study medication until least
             16 weeks after the last dose of study medication.

          -  Adequate organ system function.

          -  Ability to comply with dietary and tobacco/alcohol abstinence requirements.

        Exclusion Criteria

          -  Haematological malignancy associated with human immunodeficiency virus (HIV)
             infection or solid organ transplant or history of known Hepatitis B Antigen or
             positive Hepatitis C antibody (confirmed by Recombinant ImmunoBlot Assay [RIBA], if
             available or alternately confirmed by Hepatitis C Virus [HCV] RNA).

          -  History or concurrent malignancy of solid tumours, except for below. Exception:
             Subjects who have been disease-free for 5 years, or subjects with a history of
             completely resected non-melanoma skin cancer or successfully treated in situ
             carcinoma are eligible. Subjects with second malignancies that are indolent or
             definitively treated may be enrolled even if less than 5 years have elapsed since
             treatment. Consult the GSK Medical Monitor if unsure whether second malignancies meet
             requirements specified above.

          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immuno- therapy,
             biologic therapy, hormonal therapy, surgery, and/or tumour embolization).The
             following are allowed: Hydroxyurea for proliferative disease, Corticosteroids for
             leukemia, Use of hematopoetic growth factors is permitted at the discretion of the
             investigator according to published guidelines (e.g., National Comprehensive Cancer
             Network (NCCN), American Society of Clinical Oncology (ASCO), American Society of
             Hematology (ASH), etc.). The following are NOT allowed: Investigational anti cancer
             drug within 2 weeks (or 5 half-lives of the drug, whichever is longer) prior to the
             first dose of GSK525762; Major surgery, radiotherapy, or immunotherapy within 4 weeks
             of GSK525762 Chemotherapy regimens with delayed toxicity within the last 4 weeks.
             Chemotherapy regimens given continuously or on a weekly basis with limited potential
             for delayed toxicity within the last 2 weeks.

        Nitrosourea or mitomycin C within the last 6 weeks

          -  Subjects with prior allogeneic stem cell transplant are excluded.

          -  Current use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within
             14 days prior to the first dose of GSK525762. Low dose (prophylactic) low molecular
             weight heparin (LMWH) is permitted. In addition, INR must be monitored in accordance
             with local institutional practices, as appropriate.

          -  Current use of a prohibited medication or requires any of these medications during
             treatment with the investigational drugs. This includes excluding current medications
             known or suspected to be associated QT prolongation. In addition, any subject who is
             expected to require a QT prolonging medication while on trial should not be enrolled.

          -  Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated
             respiratory, hepatic, renal, cardiac disease, or clinically significant bleeding
             episodes). Any serious and/or unstable pre-existing medical (aside from malignancy
             exception above), psychiatric disorder, or other conditions that could interfere with
             subject's safety, obtaining informed consent or compliance to the study procedures,
             in the opinion of the investigator.

          -  Symptomatic or untreated leptomeningeal or brain metastases or spinal cord
             compression, other compressive mass, uncontrolled painful lesion, bone fracture, etc
             (e.g., change in mental status, focal weakness). Subjects are permitted to enrol if
             they were previously treated for CNS leukemia or brain metastases and have had stable
             central nervous system (CNS) disease (verified with consecutive imaging studies) for
             &gt;2 months, are asymptomatic and off corticosteroids, or are on stable dose of
             corticosteroids for at least 1 month prior to study Day 1.

          -  Cardiac abnormalities as evidenced by any of the following: History or current
             clinically significant uncontrolled arrhythmias or hypertension; Clinically
             significant conduction abnormalities or arrhythmias, subjects with Bundle Branch
             Block; Presence of cardiac pacemaker; History or evidence of current &gt;=Class II
             congestive heart failure as defined by New York Heart Association (NYHA); History of
             acute coronary syndromes (including unstable angina and myocardial infarction),
             coronary angioplasty, or stenting within the past 3 months.

          -  Any of the following ECG findings or assessments including: Baseline QTcF interval
             &gt;=450 milliseconds; Clinically significant ECG assessments should be reviewed by the
             site cardiologist prior to study entry.

          -  GSK525762 is a benzodiazepine class molecule. Any serious known immediate or delayed
             hypersensitivity reaction(s) to GSK525762 or idiosyncrasy to drugs chemically related
             to the investigational drug.

          -  No evidence of pulmonary hemoptysis within the last 7 days.

          -  History of major gastrointestinal bleeding within the last 3 months or any evidence
             of active gastrointestinal bleeding excludes the subject.

          -  Presence of gastrointestinal disease that would significantly affect compound
             absorption.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>BET inhibitor</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Myelodysplastic syndromes</keyword>
  <keyword>Oncology</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>GSK525762</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
